Vermillion Profit Margin 2006-2019 | VRML
Current and historical gross margin, operating margin and net profit margin for Vermillion (VRML) over the last 10 years. Profit margin can be defined as the percentage of revenue that a company retains as income after the deduction of expenses. Vermillion net profit margin as of March 31, 2019 is -381.57%.
|Vermillion Annual Profit Margins
|Vermillion Quarterly Profit Margins
||Medical Instruments Manufacturing
Vermillion, Inc. is engaged in the discovery, development and commercialization of novel diagnostic tests that help physicians diagnose, treat and improve outcomes for patients. The Company has diagnostic programs in oncology, hematology, cardiology and women's health. Its tests are intended to guide decisions regarding patient treatment, which may include decisions to refer patients to specialists, to perform additional testing, or to assist in the selection of therapy. Vermillion also intends to address clinical questions related to early disease detection, treatment response, monitoring of disease progression, prognosis and others. Its lead product includes the OVA1 ovarian tumor triage test, which addresses presurgical identification of women who are at high risk of having a malignant ovarian tumor. In addition to the OVA1 Test, Vermillion has development programs in other clinical aspects of ovarian cancer as well as in peripheral arterial disease. Vermillion, Inc. is based in Fremont, California.